Crossmark

Evaluation of the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Dulaglutide and Sitagliptin in the Spanish Setting

Published Online: 2020-08-29

Published Print: 2020-10

Authors

Martín, Virginia

Vidal, Josep

Malkin, Samuel J. P.

Hallén, Nino

Hunt, Barnaby https://orcid.org/0000-0001-5420-279X
Funding

Funding for this research was provided by:

Novo Nordisk A/S
License Information

Text and Data Mining valid from 2020-08-29

Version of Record valid from 2020-08-29
More Information

Article History

Received: 16 June 2020

First Online: 29 August 2020

Document is current